CTSD and metabolic dysfunction-associated steatohepatitis: In line, extracellular CTSD inhibition led to increased beneficial effects in NASH compared to intracellular CTSD inhibition, including reduced hepatic triglyceride levels, increased faecal bile acids and reduced systemic inflammation.